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INTRODUCTION
Recently, the prevalence of a variety of immune disorders 
has been gradually increasing in the developed countries. One 
hypothesis for this phenomenon was lack of infectious diseas-
es, including helminthic parasite infections [1]. There are many 
reports about the negative relationship between infectious dis-
eases and immunological diseases, including asthma, rheuma-
tism, allergic diseases, cardiovascular disease, Type 1 diabetes 
mellitus, multiple sclerosis, and inflammatory bowel diseases 
(IBD) [2-7]. 
IBD may derive from an abnormal host immune responses 
to normal commensal enteric bacteria, leading to a loss of im-
mune tolerance. Although the causative mechanisms of the 
IBD have yet to be thoroughly established, epidemiological 
and laboratory works suggest that environmental and genetic 
factors are crucial to their pathogenesis [8,9]. Recently, new 
therapeutic trials for IBD have been conducted using either 
parasite infections or parasite-derived material treatment. Sum-
mers et al. [10] demonstrated that Trichuris suis could be an ef-
fective treatment for active Crohn’s disease. T. suis has also pro-
ven to be effective in ulcerative colitis in a randomized trial 
conducted by the same group. In addition, experimental ani-
mal studies have revealed that infections with the helminths, 
Schistosoma mansoni, Hymenolepis diminuta, and Trichinella spi­
ralis ameliorate intestinal colitis in animal models [11-13]. Many 
researchers have already isolated several immune down-regu-
latory molecules from parasites, and these molecules have been 
identified as mammal cytokine homologues, protease inhibi-
tors (cystatin and serpin), abundant larval transcript antigens, 
and venom allergen-like proteins [14-17].
Cystatins are inhibitors of reversible cystein proteases and 
consist of 3 families; stefins (cystatins A and B, or Type I; MW 
11 kDa), cystatins (Cystatin C, E, and S, or Type II; MW 13-14 
kDa), and kininogens (Type III; 88-114 kDa) [18]. Their func-
tions in the immune system are to modulate cathepsin activi-
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Abstract: Many immune down-regulatory molecules have been isolated from parasites, including cystatin (cystain prote-
ase inhibitor). In a previous study, we isolated and characterized Type I cystatin (CsStefin-1) of the liver fluke, Clonorchis 
sinensis. To investigate whether the CsStefin-1 might be a new host immune modulator, we induced intestinal inflamma-
tion in mice by dextran sodium sulfate (DSS) and treated them with recombinant CsStefin-1 (rCsStefin-1). The disease 
activity index (DAI) increased in DSS only-treated mice. In contrast, the DAI value was significantly reduced in rCsStefin-1-
treated mice than DSS only-treated mice. In addition, the colon length of DSS only-treated mice was shorter than that of 
rCsStefin-1 treated mice. The secretion levels of IFN-γ and TNF-α in the spleen and mesenteric lymph nodes (MLNs) 
were significantly increased by DSS treatment, but the level of TNF-α in MLNs was significantly decreased by rCsStefin-1 
treatment. IL-10 production in both spleen and MLNs was significantly increased, and IL-10
+F4/80
+ macrophage cells 
were significantly increased in the spleen and MLNs of rCsStefin-1 treated mice after DSS treatment. In conclusion, rC-
sStefin-1 could reduce the intestinal inflammation occurring after DSS treatment, these effects might be related with re-
cruitment of IL-10 secreting macrophages. 
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ties and antigen presentation. Cystatins, type II cystatins in par-
ticular, have been shown to be important immuno-modulato-
ry proteins, involved in inflammatory processes, antigen pre-
sentation, and lymphocyte activation [19,20]. In addition, cys-
tatins isolated from nematode parasites can lead to drastic chan-
ges in the antigen processing and presentation of antigen pre-
senting cells (APCs) of the host [21-24]. Especially, the cystatin 
(AvCystatin) isolated from Acanthocheilonema vitae could regu-
late expression of IL-10 in the host macrophages. This up-regu-
lation reduced both the allergic response and the intestinal in-
flammation [25]. 
Although most of the stefins were expressed intracellularly, 
some stefins have been recently isolated from parasite excreto-
ry-secretory proteins. Therefore, parasite stefins might also have 
immunomodulatory functions, in a manner similar to nema-
tode cystatins [26]. Previously, Kang et al. [27] isolated a stefin 
(CsStefin-1) from the liver fluke Clonorchis sinensis. CsStefin-1 
was shown to be an active cysteine protease inhibitor; it was 
able to inhibit the protease activity of cathepsin Fs from C. si­
nensis (CsCFs), as well as human cathepsin B, human cathep-
sin L, and papain [27]. The antibodies against CsStefin-1 were 
detected in the sera of rats 14 weeks after an experimental in-
fection with C. sinensis [27]. This result indicates that the pro-
tein could be released outside of the parasite, where it possi-
blly protects the parasite and host’s biliary epithelial cells from 
the strong protease activity possessed by the CsCFs. Additional 
extracellular functions, including the modulation of the host 
immune response by the CsStefin-1, are still have to be deter-
mined. Moreover, Jeong et al. [28] suggested that the C. sinen­
sis-derived total protein could attenuate the airway inflamma-
tion in the mouse asthma model by inducing regulatory T cells 
(CD4
+CD25
+Foxp3
+T, Treg), showing that C. sinensis might act 
as a host immune modulator. 
In this study, to investigate whether CsStefin-1 might be a 
new host immune modulator, mice with experimentally-in-
duced inflammation were treated with CsStefin-1, and the in-
flammation response in mice was evaluated. In addition, the 
mechanisms related to their anti-inflammation ability were 
characterized. 
MATERIALS AND METHODS
Preparation of the rCsStefin-1 protein secreted from C. 
sinensis 
In a previous study, the cystatin (CsStefin-1) of C. sinensis was 
cloned into pQE9 (Qiagen Science, Valencia, California, USA). 
Recombinant CsStefin-1 (rCsStefin-1) was expressed and puri-
fied on the basis of a previously published report [27]. Puri-
fied rCsStefin-1 was desalted by HiTrap
TM desalting column 
(Amersham Biosciences, Little Calfont, UK). Lipopolysacha-
ride (LPS) was depleted using the Detoxi-gel endotoxin remov-
ing column (Pierce, Rockford, Illinois, USA). 
Induction and assessment of colitis
Female C57BL/6 mice aged 6 weeks were purchased from 
Samtako Co. (Gyeonggi-do, Korea). This study included 3 gro-
ups; non-treated group (control), only colitis induced group, 
and rCsStefin-1 treated group (after induction of colitis). There 
were 5 mice in each group. From day 0 to day 4, mice were ad-
ministered 3% (wt/vol) dextran sulfate sodium (DSS) in drink-
ing water (molecular weight, approximately 40,000) (MP Bio-
medicals, LLC, France). From day 4 to day 8, mice were treated 
4 times with i.p. injections of rCsStefin-1 with a dose of 2 µg. 
Mice were weighed and visually observed for rectal bleeding 
and diarrhea every day, starting with day 0. The disease activity 
index (DAI) was used to assess the grade of colitis. The score 
ranges from 1 to 4, and represents the sum of the scores for 
body weight loss, stool consistency, and rectal bleeding divid-
ed by 3 (Table 1). 
Histological evaluation of colitis
The colon tissue samples were isolated from mice, and wash-
ed with PBS. Then, the tissue samples were fixed with 4% para-
formaldehyde, embedded in paraffin, mounted on glass slides, 
and stained with hematoxylin and eosin. For histological eval-
uation of the tissue damage, areas of inflammatory lesions were 
microscopically evaluated and scored, as shown in Table 2.
Cytokine production
After mice were killed, lymphocytes from their spleen and 
mesenteric lymph nodes (MLNs) were isolated to investigate 
the incidence of specific cytokine secreting lymphocytes. Spleens 
and MLNs were treated with ACK hypotonic lysis solution (Sig-
Table 1. Scoring system for the disease activity index (DAI)
Score Weight loss (%) Stool consistency Blood
1 1-3 Normal Negative hemocculture
2 3-6 Soft but still formed Positive hemocculture
3 6-9 Very soft Blood traces in stool visible
4 >9 Diarrhea Rectal bleeding  Jang et al.: Helminth cystatin inhibits intestinal inflammation via macrophage recruitment   247
ma-Aldrich, Saint Louise, Missouri, USA) for 2 min at the room 
temperature, for RBC lysis. After RBCs were lysed, the remain-
ing cells were filtered through 100 μm meshes (Small Parts 
Inc., Seattle, Washington, USA), and were plated in 48 well 
plates, as 5×10
6 cells/ml in RPMI 1640 with 10% fetal bovine 
serum (FBS) and penicillin/streptomycin. For the CD3 stimu-
lation experiments, 0.5 μg/ml of CD3 antibody (eBioscience, 
San Diego, California, USA) was added to the cell-plated well. 
Plated cells were then incubated for 72 hr at 37˚C in air con-
taining 5% CO2. After incubation, culture media were harvest-
ed and stored at -20˚C.
ELISA
ELISA tests were performed to measure IL-10, TGF-β, TNF-α, 
IL-1β, and IFN-γ in culture supernatants with the ELISA kit 
(eBioscience). Each assay was carried out according to the ma-
nufacturer’s recommended protocols. 
Realtime PCR
The colon tissue was immersed in 1 ml QIAzol (Qiagen Sci-
ence), and homogenized with a tissue homogenizer. RNA ex-
traction was performed following the manufacturer’s protocols 
(Qiagen Science), transcribing 2 µg RNA with moloney murine 
leukemia virus (M-MLV) reverse transcriptase (Promega, Madi-
son, Wisconsin, USA). IL-10 RNA levels were measured by real-
time PCR using the iCycler
TM (Bio-Rad Laboratories, Inc., Her-
cules, California, USA) real-time PCR equipment and GAPDH 
were used as reference genes. Primers were produced accord-
ing to a previous report [29]. PCR amplification was carried 
out in 20 μl solution, containing 2 µl cDNA, 0.2 μM primers, 
and the SYBR Premix Ex Taq
TM (TAKARA Bio Inc., Otsu, Shiga, 
Japan). Expression levels were estimated using the iCycler iQ
TM 
multi-color real-time PCR detection system (Bio-Rad). The rel-
ative expression of the gene was then calculated as the ratio to 
a housekeeping gene, using the gene-x program (Bio-Rad). 
Signal pathway
A mouse colon epithelial cell line (CT-26 cells) was main-
tained in Dubecco’s modified Eagle’s medium (DMEM) (Hy-
clone, Road Logan, Utah, USA), supplemented with 10% heat-
inactivated FBS (Hyclone), 100 units/ml penicillin and 100 
µg/ml streptomycin. A 1-µg/ml rCsStefin-1 protein was added 
to cells for 0, 10, 30, and 60 min. CT-26 cells were harvested 
by scrapper (Bio-Rad) and washed twice with cold PBS. The 
total protein of CT-26 cells was extracted using the PRO-PREP 
protein extraction solution (Intron Biotechnology, Sungnam, 
Korea). The extraction procedures were carried out according 
to the manufacturer’s recommended protocols. The protein 
concentration was determined by the Bradford method (Bio-
Rad). These samples were separated into 30 µg fragments by 
SDS-PAGE on 10% acrylamide gel, which were then transferr-
ed onto nitrocellulose membranes (Amersham Biosciences), 
blocked with 5% skim milk in TBS containing 0.1% triton x- 
100 (TBST) for 1 hr at room temperature, and the membrane 
was washed 5 times with TBST. To detect the proteins, the mem-
brane was incubated with appropriate antibodies. These were 
anti-mouse-pERK monoclonal antibodies (mAb) (Santa Cruz 
Bio Inc., Santa Cruz, California, USA), anti-mouse-p38 mAb 
(Cell Signaling Technology, Inc., Beverly, Massachustts, USA), 
and anti-mouse-SAPK/JNK mAb (Cell Signaling Technology). 
As the secondary antibody, the anti-mouse IgG-HRP conjugate 
was purchased from Sigma. First antibodies were used at a 1: 
1,000 dilution in 1% BSA TBST. HRP conjugated secondary 
antibodies were used at a 1:2,000 dilution. ECL substrate (Am-
ersham Biosciences, Uppsala, Sweden) was used for detection.
Flow cytometry analysis
After mice were killed, immune cells from their spleen and 
MLNs were isolated to investigate IL-10 secreting cell recruit-
ment. At first, to evaluate the recruitment of Treg cells induced 
by rCsStefin-1 treatment, isolated cells from the spleens and 
MLNs were subjected to CD4, CD25, and Foxp3 staining us-
ing FITC-labeled anti-mouse CD4, APC-labeled anti-mouse 
CD25, and Pacific Blue-labeled anti-mouse Foxp3 antibodies 
(eBioscience). The cell surfaces were then stained with anti-
mouse CD4 and anti-mouse CD25 antibody, in accordance 
Table 2. Scoring system for the histological tissue damage
Score  1 2 3 4
Number of ulcers 0 1-2 3-4 5<
Size of ulcers <100 μm 100<500 μm 500 μm <1 mm 1 mm <
Tissue destruction 0 1-2 3-4 5<
Immune cells infiltration 1-3 4-7 8-11 >11248   Korean J Parasitol Vol. 49, No. 3: 245-254, September 2011
with the manufacturer’s recommended protocols. After surface 
staining, the cells were treated for 30 min with permeabiliza-
tion buffer at 4˚C following Foxp3 staining. After treatment 
with permeabilization buffer, the cells were stained with anti-
mouse Foxp3 antibodies. 
In addition, to determine the mechanisms of elevation of 
IL-10 level by the rCsStefin-1 treatment, the immune cells were 
subjected to IL-10 staining by using the anti-mouse CD4-FITC 
labeled antibody, anti-F4/80-PerCP-blue labeled antibody, and 
PE-labeled IL-10 antibody (eBioscience). After staining with 
the surface marker, the anti-F4/80 antibodies and anti-CD4 
antibodies, the cells were treated with permeabilization buffer 
for 30 min at 4˚C, to follow the IL-10 staining. The cells were 
stained with the IL-10 antibody. Flow cytometry was perform-
ed and analyzed on the FACSCanto
TM || (BD) with the FACS 
Diva
TM 6.0 software.
Statistical analysis
All experiments were performed twice with similar results. 
Results were expressed as the mean±SD. Statistically signifi-
cant differences were determined using the Student’s t-test and 
ANOVA. 
RESULTS
Amelioration of DSS-induced intestinal inflammation after 
treatment with recombinant parasite cystatins
To investigate whether the recombinant parasite cystatin 
(rCsStefin-1) could regulate inflammation, we evaluated the 
intestinal inflammation after treatment with recombinant rC-
sStefin-1 of the DSS-induced intestinal inflammation in the 
mouse model of IBD. We observed a loss of body weight in 
the DSS-treated group, but the degree of weight loss in rCsSte-
fin-1 treated mice was lower than thqat in DSS only-treated 
mice (Fig. 1A). We evaluated the severity of colitis using the 
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Fig. 1. Examination of the clinical symptoms and histopathologic changes in the DSS-induced colitis after rCsStefin-1 treatment. (A) 
Serial changes of percentage body weight and (B) Disease activity index (DAI) were measured daily during the experimental period, 
as described in ‘Materials and Methods’. (C) The standard DAI is shown in Table 1. After the experimental period, the colon length of 
each mouse was measured. (D) To examine the histological change, colon tissues were isolated and stained. The scale is 100 μm. (E) 
The histopathologic inflammatory score is shown in. The standard histopathological score is shown in Table 2. DW+PBS, mice was 
treated with DW and PBS during the experimental period. DSS+PBS, mice were treated with PBS after DSS treatment. DSS+rCsSte-
fin-1, mice was treated with rCsStefin after DSS treatment. Scores reflected evaluation of 3 colon segments for each animal (*P<0.05 
as compared with DSS+PBS treated group, ***P<0.001 as compared with DSS+PBS treated group, n=5 mice/group, 3 indepen-
dent experiments).
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percentage of weight loss, changes in the stool states, including 
consistency, and blood presence in the stool. These measure-
ments have been employed as visible parameters for the de-
gree of inflammation in the DSS-induced colitis, and expressed 
as DAI value. The DAI value was increased on day 2 and reduc-
ed on day 7 in DSS only-treated mice, but the DAI value in rC-
sStefin-1-treated mice was reduced on day 6. The DAI value 
was significantly lower in rCsStefin-1-treated mice than those 
in DSS only-treated mice on days 7 and 8 (Fig. 1B). In cases of 
persistent diarrhea, the colon may be shortened, along with 
severe inflammation of the large intestine [30]. After the mice 
were sacrificed, we observed that the colon of DSS only-treated 
mice was shorter than the colon of rCsStefin-1 treated mice 
(Fig. 1C). These results indicated that DSS treatment might in-
duce severe inflammatory responses in the colon, but these re-
sponses seemed to be inhibited by the rCsStefin-1 treatment. 
Fig. 1D showed histological changes in the colon after DSS 
and/or rCsStefin-1 treatment. In the histological examination, 
the colon of control mice maintained structurally intact epi-
thelium and submucosal layers (Fig. 1D-a). However, the sub-
mucosal layers of the colon in DSS-treated mice showed a va-
riety of inflammatory cell infiltrations and ulcerative mucosa, 
as well as destructed crypt cells in the epithelium (Fig. 1D-b). 
In contrast, the majority of the epithelium was intact and the 
crypt cells and ulcerative lesions were only rarely detected in 
the colon of rCsStefin-1- treated mice (Fig. 1D-c). The tissue 
histopathology index scores were significantly higher in DSS-
treated mice than those in mice treated with rCsStefin-1 after 
DSS-treatment (Fig. 1E). These results demonstrated that rC-
sStefin-1 treatment may facilitate the repair of the ulcerations 
induced by DSS.
TNF-α production in MLNs was inhibited by rCsStefin-1 
treatment, but IL-10 production was elevated
To investigate the mechanism of protection against intesti-
nal inflammation elicited by rCsStefin-1, we evaluated IFN-γ, 
TNF-α, IL-1β, and regulatory cytokine levels of lymphocytes 
isolated from MLNs and spleen of mice with DSS-induced in-
testinal inflammation after rCsStefin-1 treatment (Fig. 2). The 
secretion levels of IFN-γ, TNF-α, and IL-1β of splenocytes were 
Fig. 2. The level of Th1-related cytokines in the spleen and MLNs. The level of cytokine production from lymphocytes in the spleen 
(upper) and MLNs (lower) was measured by ELISA. The lymphocyte was isolated from the spleen and MLNs, and stimulated with an-
ti-CD3 antibody. After stimulation, the Th1 cytokine, IFN-γ, TNF-α, and IL-1β were measured. The ratio of each cytokine secretion 
level from non-stimulated state to stimulated state was compared with those in other groups and this ratio was used for the ANOVA 
(*P<0.05, **P<0.01, ***P<0.001, n=5 mice/group, 3 independent experiments).
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significantly increased after the DSS treatment, but those levels 
were not significantly reduced after rCsStefin-1 treatment (Fig. 
2). However, the levels of TNF-α in MLNs of the rCsStefin-1- 
treated mice were significantly reduced. The levels of IFN-γ and 
IL-1β in MLNs were not changed by rCsStefin-1 treatment. To 
characterize the inhibitory mechanisms of the inflammatory 
related cytokines production, we evaluated the Treg cell recruit-
ment and the Treg related cytokine production. The results show-
ed that IL-10 level was significantly increased by rCsStefin-1 
treatment in both the spleen and MLNs. However, the level of 
TGF-β was not changed (Fig. 3). The population of the Treg cells 
was not changed by the rCsStefin-1 treatment both in the spleen 
and MLNs (Fig. 3). 
IL-10 secreting macrophage was increased by 
rCsStefin-1 treatement
To know increased IL-10 secreting cell subtype, we analyzed 
IL-10
+, CD4
+, and F4/80
+ (macrophage-specific surface mark-
er) cell population. In addition, we evaluated another macro-
phage specific gene (CD33) expression level in the large intes-
tinal tissue after DSS and rCsStefin treatments [31,32]. We found 
IL-10
+ CD4
+ cell population in the spleen and MLNs was not 
changed by CsStefin-1 treatment on DSS treated mice (data 
not shown). Although the population of IL-10 secreting T cells 
was not changed, the IL-10
+F4/80
+ macrophage cell popula-
tion was significantly increased both in the spleen and MLNs 
by CsStefin-1 treatment on DSS treated mice (Fig. 4A). In ad-
dition, we found CD33 and IL-10 gene expression level in large 
intestine of rCsStefin-1 treated mice was significantly higher 
than those of only DSS treated mice (Fig. 4B). We found IL-
10
+F4/80
+ cells production in the MLNs could be significantly 
increased by rCsStefin-1 treatment in normal mice (Fig. 4C). 
IL-10 was produced by rCsStefin-1 treatment via the 
ERK pathway
We found that the IL-10 expression level in the large intesti-
nal tissue was significantly increased by rCsStefin-1 treatment 
(Fig. 4B). We also conducted western blotting to evaluate the 
MAPKs phosphorylated by rCsStefin-1 in intestinal epithelial 
cells. As a result, at 10, 30, and 60 min after rCsStefin-1 treat-
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ment, the phosphorylation of both ERK were induced, at a 
concentration of 1 μg/ml (Fig. 5A), whereas rCsStefin-1 did 
not activate the phosphorylation of p38 and SAPK/JNK in CT-
26 cells (data not shown). To further evaluate the role of MAPK 
in IL-10 production, we conducted real-time PCR. We employ-
ed inhibitors of specific MAPKs, and examined the effects of 
the PD98059 (ERK1/2 inhibitor) on the CT-26. The up-regula-
tion of IL-10 induced by the rCsStefin-1 in the CT-26 cells was 
prevented by pretreatment with PD98059 (Fig. 5B). 
DISCUSSION
In previous report, Kang et al. [27] identified and character-
ized the type I cystatin (CsStefin-1) isolated from the liver fluke 
C. sinensis. Type I cystatins are generally described as intracel-
lular cystein protease inhibitors. They are also found in various 
body fluids in healthy humans [33,34]. In addition, the CsSte-
fin-1 was expressed throughout various developmental stages 
of the parasite, from metacercaria to the adult worm [27]. The 
structure of the CsStefin-1 (Type I cystatin) is different from the 
Type 2 cystatin (i.e. the filarial cystatin). Type I cystatins have 
no SND motif which could inhibit either the legumain, or the 
asparaginyl endopeptidase. Legumain like asparaginyl endo-
peptidases are important for the intracellular processing of an-
tigens for presentation with the MHC class II [35]. Although 
there is no evidence that the CsStefin-1 could block the anti-
gen processing of the host or not, probably this might not oc-
cur. However, it has been shown that the CsStefin-1 had an-
other immune modulating function, which was activation and 
proliferation of the IL-10 secreting macrophages. 
In the IBD pathogenesis, the imbalance between proinflam-
matory cytokines (IL-1, IL-1β, IL-2, IL-6, IL-8, IL-12, IL-17, IL- 
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Fig. 4. IL-10 secreting macrophage cell was increased by rCsStefin-1 treatment. (A) IL-10 secreting macrophage population in the 
spleen and the MLNs in rCsStefin-1 treated mice after DSS treatment was measured by FACS. After the IL-10
+ cells were gated, the 
percentage of the F4/80
+IL-10
+ cells among the IL-10
+ cells was analyzed. (B) Macrophage specific surface marker CD33 gene and 
IL-10 gene expression level in large intestine tissue was evaluated by realtime PCR. (C) The incensement of IL-10
+F4/80
+ cell popula-
tion by rCsStefin-1 treatment in normal mice was evaluated by FACS. One µg rCsStefin-1 or only PBS was injected i.p. 4 times and 
immune cells were isolated from each mouse MLNs. The PBS treated mice were used as the control group. The F4/80
+ subset pop-
ulation was analyzed after IL-10
+ cell gating (**P<0.01, ***P<0.001, n=5 mice/group, 3 independent experiments). 252   Korean J Parasitol Vol. 49, No. 3: 245-254, September 2011
23, TNF-α, and IFN-γ) and anti-inflammatory cytokines (IL-4, 
IL-10, IL-11) is also important [36]. Especially, the TNF-α is the 
key cytokine in the pathogenesis of IBD. Therefore, most use-
ful therapeutic agents against IBD were antibodies against TNF-α 
cytokines, such as infliximab, adalimumab, and certolizumab 
[36,37]. Severe forms of colitis, such as the Crohn’s disease re-
fractory to conventional therapy, fistulizing Crohn’s disease 
and chronic active ulcerative colitis, generally respond well to 
the anti-TNF-α therapy. However, this medication can cause 
serious side effects, that usually occur, careful monitoring of 
the therapy should be performed [38,39]. Potential side effects 
of anti-TNF therapy include opportunistic infections, antibody 
formation against anti-TNF, and risks of lymphomas in the 
IBD patients [37,39]. New therapeutic methods should be 
continually investigated. Although the overall effect was not 
dramatic, the rCsStefin-1 treatment inhibited the level of the 
TNF-α cytokines in the MLNs (Fig. 2). These results suggest 
that rCsStefin-1 could be considered as a new anti-TNF agent. 
Inhibition of the TNF-α production might occur due to in-
crease of anti inflammatory cytokine IL-10 production. We ob-
served that the IL-10 production was significantly increased by 
the rCsStefin-1 treatment, in both the spleen and the MLNs 
(Fig. 3). In addition, the IL-10 mRNA level in large intestine 
tissue was increased on rCsStefin-1 treatment (Fig. 4B). The IL-
10, which is referred to as the cytokine synthesis inhibitory fac-
tor, is an anti-inflammatory cytokine capable of inhibiting the 
synthesis of pro-inflammatory cytokines [40]. The IL-10 defi-
cient mice develop IBD following colonization of the gut with 
particular microorganisms [41]. The helminthic parasites stim-
ulate the production of immunoregulatory mediators, which 
likely play a role in the maintenance of the chronicity of infec-
tion, without any marked induction of pathology. In particu-
lar, elevated levels of IL-10 and TGF-β have been associated 
with both the helminth infection, and the helminth-derived 
molecule treatment [9,29]. The IL-10 is mainly generated by 
the Treg cells, and both the IL-10 and the TGF-β cytokines have 
been shown to induce Treg cell differentiation [42]. The Treg cells 
perform a crucial function in the prevention of uncontrolled 
inflammatory responses, including IBD [43]. However, in this 
study, the population of Treg cells has not been changed by the 
rCsStefin-1 treatment (Fig. 3). Moreover, the TGF-β cytokine, 
which was very important for activation and proliferation of 
the Treg cells, was not increased in both the spleen and the MLNs. 
Therefore, we thought that inhibition of intestinal inflamma-
tion after rCsStefin-1 treatment might be not due to Treg cell ac-
tivation, but due to other IL-10 secreting cells. In this study, we 
found IL-10
+F4/80
+ macrophage in the spleen and the MLNs 
was significantly increased by rCsStefin-1 treatment in DSS 
treated mice (Fig. 4A). In addition, we found macrophage spe-
cific CD33 gene expression in large intestine of rCsStefin-1 treat-
ed mice after DSS treatment was significantly higher than those 
of DSS treated mice (Fig 4B). These results showed that IL-10
+ 
macrophage cell subset played a role in elevation of IL-10 by 
CsStefin-1 treatment. In previous reports suggested that activa-
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tion and proliferation of the IL-10 secreting macrophages was 
also increased by other parasite cystatin treatment [24,25]. In 
vitro, in intestinal epithelial cell lines, we have demonstrated 
that rCsStefin-1 induced IL-10 gene expression via phosphory-
lation of the MAPK ERK1/2 and that their expression was par-
tially blocked by ERK1/2 inhibitors (Fig. 5). Although IL-10 
expression may involve signaling via the ERK1/2 MAPK path-
way, there might be possibility of another pathway involv  ed in 
this expression because of IL-10 expression was not completely 
blocked by ERK1/2 inhibitor. In a recent study, it was demon-
strated that parasite cystatin (AvCystatin, Type 2 cystatin) may 
also trigger an ERK1/2 and p38-dependent signal transduction 
pathway in the mouse macrophage [24]. 
Parasites regulate or suppress their host immune responses 
to maintain their parasitism for a prolonged period; the mole-
cules governing this process are not yet identified. In this study, 
we determined that rCsStefin-1 may be one of these molecules 
regulating the host immune; thus rCsStefin-1 could prove use-
ful in the design of novel therapeutic intervention strategies for 
IBD.
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